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Abstract The aimofthe studywas to investigate changesinin£ammatorymarkers followingemergency treatmentof
obstructivepulmonarydisease.The studycomprised 43 patients.After acutetreatment, theyweregiveneither 30mgof
prednisolone p.o. or1600 mg of inhaled budesonide daily for1week.Over the following 3 weeks, all the patients were
given 1600 mg of inhaled budesonide daily. Blood samples for measurements of eosinophil cationic protein (S-ECP),
eosinophil peroxidase (S-EPO), total eosinophil count (B-Eos), myeloperoxidase (S-MPO) and humanneutrophil lipoca-
line (HNL) were taken and spirometrywasperformedbefore emergency treatment and after1and 4 weeks.Therewas
no di¡erence in the improvement in forced expiratory volume in 1sec (FEV1) between patients given prednisolone or
budesonide.Patients with an improvement in FEV1of 20% of baseline after1and 4 weeks displayed a larger decrease
ineosinophilmarkers.ThecorrelationbetweenDFEV1andDS-ECPwas r=70?37,P50?05,DS-EPO70?40,P50?01and
DB-Eos70?44,P50?01, after 4weeks.Thiscorrelationwashighlysigni¢cantinpatientswhohadsmoked 5 pack-years,
while the correlation was not signi¢cant in patients with a longer smoking history and chronic air£ow limitation (best
FEV1580% of predicted).We conclude that the change in eosinophil markers is correlated to the improvement in
lung function in non-smokers or short-term smokers following the emergency treatmentof obstructive pulmonary dis-
ease. This study indicates that following eosinophil markers is more useful in patients with asthma than patients with
COPD.c 2001Harcourt Publishers Ltd
doi:10.1053/rmed.2001.1179, available online athttp://www.idealibrary.comon
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Asthma and chronic obstructive pulmonary disease
(COPD) are both characterized by bronchial in£amma-
tion. In asthma, one of the most important cells is
the eosinophil granulocyte (1), while the neutrophil cell
plays an important role in COPD (2, 3). Eosinophil
markers such as total eosinophil count and S-ECP have
been used to monitor disease activity, especially
during treatment with inhaled steroids (4^6).There are,
however, not many studies on eosinophil markers afterReceived 24 November 2000, accepted in revised form June 2001and
published online13 September 2001.
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(7, 8).
We have previously reported that patients with high
levels of eosinophil markers before emergency treat-
ment experienced a greater improvement in lung func-
tion (9).This investigationwas based on common clinical
practice at the emergency unit, with a heterogeneous
group of patients seeking medical help because of an
acute exacerbation of their obstructive pulmonary
disease. It comprised both asthma and COPD patients
as it is often di⁄cult, especially in the acute phase, to
distinguish asthma from COPD and some patients have
an overlap syndrome.
The aim of the investigationwas to study the changes
in eosinophil markers following emergency treatment in
patients with exacerbations of obstructive pulmonary
disease.
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Subjects
The study population in this investigation has been pre-
viously described (9). It comprised adult patients (418
years) with acute exacerbations of obstructive pulmon-
ary disease, both asthma and COPD, presenting during
the daytime at the emergency room in our department.
They were all assessed as being in need of emergency
treatment including steroids. The patients were to be
free of oral steroids and their daily dose of inhaled ster-
oids was maximized at 1600mg (800mg, if £uticasone
was used).They were excluded from the study if hospital
admission was deemed necessary or if they were unable
to perform the lung function tests. All participationwas
voluntary and the study was approved by the ethics
committee at the Medical Faculty at Uppsala University.
Before treatment, all the patients were examined and
spirometry (Vitalograph Alfa, Vitalograph Ltd. Bucking-
ham,U.K.) was performed.Thepredicted value of forced
expiratory volume in1sec (FEV1) was calculated for each
patient (10).Blood sampleswere taken before treatment
was given.Thepatientswere carefully interviewed about
their smoking history and the number of pack-years was
calculated. At the follow-ups after 1 week (visit 2) and
after 4 weeks (visit 3), spirometry was performed and
blood samples were taken.
Treatment
The treatment given in this investigation has been de-
scribed previously (9). All the patients were given
5^15mg of nebulized salbutamol (in one to three doses)
viaVentstreamwith a Porta Neb compressor (Medic Aid
Ltd, West Sussex, U.K.). The ¢rst 28 patients were
included aspartof amulti-centre study. After randomiza-
tion, they were treated with 8 mg of nebulized budeso-
nide (264mg), 60mg of prednisolone p.o. or placebo. At
discharge and at bedtime on the ¢rst day, patients who
had received nebulized budesonide or placebo in the
acute phase received one dose of 400mg of budesonide
via a dry powder inhaler (Turbohaler1) and the patients
who had received prednisolone in the acute phase were
given placeboTurbohaler1. The next morning, predniso-
lonepatients startedwith 30mgof prednisolone daily for
1week and the remaining patients continuedwith 400mg
of budesonide Turbohaler1 q.i.d. for 1 week. Up to this
point, the study was strictlydouble-blind. After complet-
ing themulti-centre study, a local study was conducted in
Uppsala with a further 22 patients in whom the treat-
ment was open and comprised 60mg of prednisolone
p.o. in the acute phase and 30mg of prednisolone p.o the
following week as described earlier (9). Apart from the
treatment, the same study protocol was followed as in
themulti-centre study. After1week, all the patients con-
tinued with 800mg of budesonideTurbohaler1 b.i.d. Atthe follow-up after 1 and 4 weeks, a new spirometry ex-
aminationwas performed.
Serum
Venous blood was collected in SST-Vacutainer tubes and
serum was prepared by allowing blood to clot for
60^120min at 208C, followed by centrifugation at1600g
at 48C for 10min. The serum samples were kept at
7708C pending analysis.
In£ammatorymarkers
As eosinophil markers, eosinophil cationic protein
(S-ECP), eosinophil peroxidase (S-EPO) and total eosino-
phil count (B-Eos) weremeasured, andmyeloperoxidase
(S-MPO), human neutrophil lipocaline (S-HNL) and total
neutrophil count (B-Neutro) were measured as neutro-
philmarkers.
Eosinophil cationic protein (ECP) was measured using
the Pharmacia CAP system ECP FEIA (Pharmacia &Up-
john Diagnostics AB,Uppsala, Sweden), according to the
manufacturer’s instructions. The inter- and intra-assay
variation was less than 8% and the detection limit was
2m gl71.
Eosinophilperoxidase (EPO)was assessedusing aproto-
type immuno£uorometric assay utilizing the Pharmacia
CAP system. Brie£y, EPO, puri¢ed with some modi¢ca-
tions according to the previously described method (11),
was used as a standard ranging from 0.5 to 200mgl71.
Monoclonal antibodies (MoAbs) were produced using the
hybridoma technique.One MoAbwas covalently bound to
the immunoCAP and the other MoAb was labelled with
the enzyme b-galactosidase. The assay procedures were
identical to those for ECP.Cross-reactivity with ECP and
myeloperoxidase (MPO) in the EPO assay was50?3 and
50?01%, respectively.The detection limit for the EPO as-
say was 0?5mgl71and the inter- and intra-assay coe⁄cient
of variationwas less than10%.
Myeloperoxidase (MPO)wasmeasuredusingradio im-
munoassays, according to the manufacturer’s instruc-
tions (Pharmacia MPO RIA, Pharmacia & Upjohn
Diagnostics AB) and human neutrophil lipocaline (HNL)
was measured as previously described(12). Inter- and
intra-assay variations were less than10% and the detec-
tion limit was 8mgl71and 4mg l71respectively.
Total neutrophil and total eosinophil counts (B-Neutro,
B-Eos) were measured using standard techniques at the
hospital’s Department of Clinical Chemistry.
Statisticalmethods
The statistical analyses were performed using the Stat
View SEgraphics software from Abacus Concepts Inc.
Comparisons between patients were performed using
Fig. 1. The change in S-ECP,S-EPOand B-eos after 4 weeksin
relationto the change in lung function (DFEV1% of baseline).The
boxplots show thevalues ofthemedian, the 25th and 75th per-
centiles (box) and the 10th and 90th percentiles. D FEV1420%
(&) and D FEV1420% ( ).P50?05, **P50?01.
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while the chi-square test was used for comparisons of
proportions. Wilcoxon’s signed-rank test was used to
study changes in in£ammatory markers. Correlations
between continuous variables on an ordinal scale were
performed using Spearman’s rank correlation test. A
P-value of 0?05 or less was regarded as statistically
signi¢cant.
RESULTS
Fifty patients participated in the study at the ¢rst visit,
but sevenpatients subsequentlydroppedout.This analysis
is based on the 43 patients who completed the whole
4-week study period. The mean age was 64 (range
22^87) years and there were 23 (53%) women and 20
men. The mean number of pack-years was 20 (range
0^76) years. Four patients were current smokers and
eight patients were lifetime non-smokers. FEV1 was
49+24% of predicted (mean+SD).
The levels of in£ammatorymarkers at the emergency
visit and at the follow-ups after1and 4 weeks are shown
in Table 1. All the eosinophil markers had decreased
signi¢cantly at visit two compared with the emergency
visit. By visit three, S-EPO and B-Eos had increased sig-
ni¢cantly. The neutrophil markers S-MPO and S-HNL
showed a slightbut signi¢cantdecrease at visit two com-
paredwith visit one. B-Neutro showed an increase from
visit one to visit two.
Patients with an improvement in FEV1 of 20% of
baseline after 4 weeks displayed a larger decrease in eo-
sinophil markers, which is illustrated in Fig.1.The corre-
lations between DFEV1 (% of baseline) and DS-ECP, DS-
EPO and DB-Eos after1week were70?26,NS;70?46,
P50?01; and70?43, P50?05, respectively. The correla-
tions between DFEV1 (% of baseline) and DS-ECP, DS-
EPO and DB-Eos after 4 weeks were 70?37, P50?05;
70?40, P50?01; and 70?44, P50?01, respectively. No
correlations were seen between the neutrophil markers
and DFEV1.Table 1. Levels of in£ammatorymarkers at visits one, two and
Visit1
(0 h)
S-ECP (mgl71) 30 (22)
S-EPO (mgl71) 38 (40)
B-Eos (106l71) 467 (330)
B-Neutro (109l71) 4.9 (2.6)
S-MPO (mgl71) 762 (496)
S-HNL (mgl71) 134 (67)
*P50?05, ***P50?001comparedwithvisit1.
{P50?05, {{{P50?001comparedwithvisit 2.Twenty-eight patients were given oral steroids during
the ¢rst week after the emergency treatment. These
patients displayed a more pronounced decrease in eosi-
nophil markers at visit two than those treated with in-
haled steroids. The e¡ect of oral steroids on the
eosinophil markers is illustrated in Fig. 2. B-Neutro only
increased signi¢cantly atvisit two in thegroupwhichwas
given oral steroids for the ¢rst week. No di¡erences
were seen in the levels of S-MPO and S-HNL between
patients who did or did not take steroids orally during
the ¢rst week. DFEV1 did not di¡er between patients
treatedwith oral steroids or not.
Nine patients relapsed during the ¢rst week and
received emergency treatment, including steroids. Dur-
ing the last 3 weeks, another three patients relapsed.
These patients did not di¡er from the others in terms ofthree.Mean (+SD).
Visit 2
(1week)
Visit 3
(4 weeks)
17 (13)*** 20 (16)***
14 (20) *** 24 (25)***, {
192 (184) *** 343 (243)*, {{{
6?4 (2?7) *** 4.4 (1?4){{{
639 (366)* 636 (354)*
118 (49)* 110 (47) ***
Table 2. ThecorrelationbetweenDFEV1 (as%of baseline) andDeosinophilmarkersafter1and 4weeksinrelationto smoking
history andbest FEV1 (Spearman’s rankcorrelationtest).
Non-or short-term
smokers
( 5 pack-years)
(n=14)
Long-term smokers
with FEV180% of predicted
(n=10)
Long-term smokers
with FEV1580% of predicted
(n=19)
DS-ECP1week 70?52 70?45 70?09
DS-EPO1week 70?74** 70?38 70?24
DB-Eos1week 70?63* 70?60 70?38
DS-ECP 4 weeks 70?59* 70?52 70?32
DS-EPO 4 weeks 70?72** 70?53 70?13
DB-Eos 4 weeks 70?79** 70?89* 70?28
*P50?05, **P50?01.
Fig. 2. Eosinophilmarkers and e¡ectof oral steroids.Patientswho relapsed are excluded (mean+SE). Steroids p.o. (D), no steroids
p.o. (&). *P50?05.
894 RESPIRATORYMEDICINEin£ammatorymarkers, smoking history or lung function
at the start of the study.
Relation to smoking history and lung
function
The correlations between the change in lung function
and the change in eosinophilmarkers were also analysed
in relation to smoking history and lung function. Patients
were divided into three groups. One group comprised
patients who had smoked for 5 pack-years or less (non-
or short-term smokers) (n=14).The second group com-
prised patients who had smoked for more than 5 pack-
years (long-term smokers) and had an FEV1 that at least
once during the studyperiodwas80% of thepredicted
(n=10). The third group were long-term smokers with
chronic air£ow obstruction (best FEV1580%predicted
during the study period) (n=19). In the non- or short-
term smoking group, the mean number of pack-years
was 0?9+1?7 (n=14) and, in the two other group the
mean number of pack-years was 30+18 (n=29). In the
long-term smoking group without chronic air£ow
obstruction there was a signi¢cant correlation between
change B-Eos and FEV1after1month.Except for this, the
change in FEV1 (D) was signi¢cantly correlated to thechange in eosinophil markers only for non- or short-
term smokers. (Table 2).
The levels of the eosinophil and neutrophil in£amma-
torymarkers did not di¡er between short- or long-term
smokers with one exception, both groups of long-term
smokers had signi¢cantly higher serum levels of S-MPO
at visit one than the non- or short-term smoking group
(Figs 3 and 4). There were no signi¢cant di¡erences in
change of eosinophilmarkers between the groups,while
there was a signi¢cant decrease in S-HNL in both the
long-term smoking groups compared to the non- or
short-term smoking group 1week after the emergency
visit.
FEV1was at all time-points lower in the long-term smo-
kers with chronic air£ow obstruction. The reversibility
in terms of the change (D) in FEV1expressed as a percen-
tage of baseline, FEV1% predicted or FEV1 (in litres) during
the study period did not di¡er between the three groups,
nor was it correlated to pack-years.
DISCUSSION
This study was performed on consecutive patients with
an acute exacerbation of obstructive pulmonary disease
Fig. 3. Eosinophilmarkersinnon- or short-termsmokers (45 pack-years) (&) andinlong-termsmokers (4 5 pack-years) without
( ) andwith chronic air£owobstruction (best FEV1580% of predicted) (&).
Fig. 4. Neutrophilmarkersinnon- or short-termsmokers (45 pack-years) (&) andinlong-termsmokers (45 pack-years)without
( ) andwith chronic air£owobstruction (best FEV1580% of predicted) (&). *P50?05 compared to non- or short-term smokers.
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previous diagnosis of asthma, COPD or both. The main
¢ndings of the study are that, for all patients, the decline
in eosinophil markers in blood the followingmonth cor-
related to the improvement in lung function. If patients
were grouped according to smokinghistory, this correla-
tion was, however, only signi¢cant in patients with a
smoking history of  5 pack-years. The neutrophil
markers, S-MPO and S-HNL, decreased after the emer-
gency visit, but the decrease did not correlate to the
change in lung function, regardless of smoking history.
In this study we have primarily chosen to study the
impact of smoking history and lung function rather than
grouping the patients on the basis of diagnosis.We haveanalysed our data with respect to smoking history,
expressed as pack-years, with information that was
obtained from the patient in an interview. In our study,
we used an arbitrary cut-o¡ point of 5 pack-years to
distinguish never-smokers and short-term smokers from
long-term smokers.No de¢nite threshold exists when it
comes to themagnitude of smoking and the riskof devel-
oping COPD. Mensinga et al., however, found that a
smoking history of at least 10 pack-years was associated
with a signi¢cantly lower FEV1 (13).We therefore chose a
cut-o¡ value of 5 pack-years in order to ensure that the
patients in the short-term smoking group were purely
asthmatics. In the long-term smoking group an FEV1
lower than 80% of thepredictedduring the study period
896 RESPIRATORYMEDICINEwas used to de¢ne the group of long-term smokers with
chronic air£ow obstruction. This cut-o¡ point was
chosen on thebasis of the BritishThoracic Societyguide-
lines (14), in an attempt to separate patients fromCOPD
from asthmatics with a long smoking history.When we
compared this classi¢cation with the patients clinical
diagnoses we found a fairly good agreement. All patients
except two who were non-smokers or short-term
smokers had a clinical diagnosis of asthma prior to the
study, while 15 of the 19 patients who were long term
smokers and had chronic air£ow limitation had a clinical
diagnosis of COPD.
We have shown that an improvement in lung function
follows a decline in eosinophil markers in blood after an
acute exacerbation. The same result has been demon-
strated in studies by Skedinger and Zimmerman (5, 7),
but there have also been studies that reveal a lack of cor-
relation (15,16). In one study, the impactof smokingon the
e¡ect of steroid treatment has been studied. Pedersen
et al. showed that smoking asthmatics did not improve in
terms of lung function after treatment with inhaled ster-
oids, nor did the eosinophil markers decrease (17). In our
study, DFEV1 did not di¡er between non- or short-term
smokers and long-term smokers, even if the long-term
smokers with chronic airway obstruction had a lower
FEV1during the study.However, only four of our patients
were current smokers. Eosinophil markers also
decreased after emergency treatment in both the long-
term smoking group, but our data show that this decline
was very poorly correlated to the improvement in FEV1,
and especially so in the group with chronic air£ow
obstruction. In contrast, a strong negative correlation
was found between the decline in eosinophil markers in
blood and DFEV1in non-or short-term smokers.
Previous studies have found that the eosinophils and
eosinophil markers are increased in acute ecxacerba-
tions of both asthma and COPD (8, 18). The increased
involvement of eosinophils in the lungs of patients with
COPD was previously suggested by high sputum levels
of these markers and by biopsy ¢ndings of the lung par-
enchyma (9, 19, 20). It is, however, of interest that the
change in eosinophil markers only correlated to change
in lung function in the non- or short-term smoking
group, which is the group of patients whichmainly com-
prises asthmatics, and not to the lung function in long-
term smokers, who are assumed to be predominantly
COPD patients. These ¢ndings suggest di¡erent
mechanisms for the activation and attraction of eosino-
phils in these two disorders and also suggest that eosino-
phils play di¡erent roles in these two conditions.
In recent studies, large numbers of neutrophils were
found in the sputumof asthmatic patientswith exacerba-
tions (21, 22). Similarly we demonstrated in a previous
study that the serum levels of MPO were raised in a
group of asthmatics and that these elevated levels
normalized upon successful treatment with inhaledcorticosteroids (17). HNL is an exclusive marker of neu-
trophils, whereas MPO also originates from activated
monocytes. The fact that S-MPO was further higher in
both groups of long-term smoking patients than in non-
or short-term smokers could therefore indicate the acti-
vation ofmonocytes as partof the in£ammatoryprocess
in COPD.
In this study, we have assessed in£ammatory markers
in blood, which have the disadvantage of being indirect
indices of airway in£ammation.On the other hand, blood
samples are safe, inexpensive and tolerated by most
patients except small children.
We conclude that, after the treatment of acute
exacerbations of obstructive pulmonary disease, the
change in eosinophil markers is correlated to the
improvement in lung function. This correlation is, how-
ever, only seen in non-smokers and short-term smokers.
Theneutrophilmarkers didnotdisplay any correlation to
lung function regardess of smoking history.Our data im-
ply that it is more valuable to follow eosinophil markers
in patients with asthma than in patients with COPD.
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